Mereo BioPharma (MREO) reported second-quarter 2026 financial results, including a net loss of $7.0 million, compared with a net loss of $14.6 million in the second quarter of 2025. Revenue was zero for the quarter, compared with $0.5 million a year earlier.
The company said cash and cash equivalents were $30.1 million as of June 30, 2026, and are expected to fund operations into late 2027. Mereo also highlighted its option and license agreement with Sentynl Therapeutics for alvelestat and ongoing regulatory engagement with Ultragenyx on setrusumab.
- R&D expenses fell to $1.8 million from $5.4 million in the year-earlier quarter.
- G&A expenses declined to $5.2 million from $5.5 million in the second quarter of 2025.
- Mereo may receive $40 million in upfront and R&D payments if Sentynl exercises the alvelestat option.
- The company said further updates on the potential path forward for setrusumab are expected by year-end 2026.
- Total ordinary shares issued as of June 30, 2026, were 798,093,044.
$MREO Hedge Fund Activity
We have seen 28 institutional investors add shares of $MREO stock to their portfolio, and 37 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ added 8,169,795 shares (+32048.5%) to their portfolio in Q1 2026, for an estimated $2,696,032
- NEWTYN MANAGEMENT, LLC added 6,854,434 shares (+3051.5%) to their portfolio in Q1 2026, for an estimated $2,261,963
- SCHONFELD STRATEGIC ADVISORS LLC removed 6,090,381 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,009,825
- ECOR1 CAPITAL, LLC added 5,512,389 shares (+70.2%) to their portfolio in Q1 2026, for an estimated $1,819,088
- MILLENNIUM MANAGEMENT LLC added 3,475,457 shares (+4155.0%) to their portfolio in Q1 2026, for an estimated $1,146,900
- 683 CAPITAL MANAGEMENT, LLC removed 3,025,000 shares (-20.1%) from their portfolio in Q1 2026, for an estimated $998,250
- LOGOS GLOBAL MANAGEMENT LP removed 1,850,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $610,500
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
